Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Phase 1

Completed

• Conditions: Advanced Tumor

• Registration Number: NCT00502060
• Lead Sponsor: AstraZeneca

Brief Summary

Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2004-08
• Primary Completion: 2006-06
• Study Completion: 2006-06
• Study First Submitted: 2007-07-13
• Study First Submitted QC: 2007-07-13
• Study First Posted: 2007-07-17
• Status Verified: 2009-05
• Last Update Submitted: 2009-05-13
• Last Update Posted: 2009-05-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

• tumor progressed on standard therapy or ineligible for standard therapy
• life expectancy of 12 weeks or more
• WHO performance status 0-2

Read More

Exclusion Criteria

• History of active interstitial lung disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
primary objective is to determine the safety and tolerability of multiple oral doses fo AZD2171 when co-administered with fixed daily oral doses of ZD1839

Secondary Outcome Measures

Name	Time	Method
to explore the PK of AZD2171 when given alone for 7 days and in combination with ZD1839 for 14 days

Trial Locations

Locations (1)

Research Site; 🇳🇱 Utrecht, Netherlands